A detailed history of Eagle Bay Advisors LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Eagle Bay Advisors LLC holds 489 shares of EXEL stock, worth $17,789. This represents 0.01% of its overall portfolio holdings.

Number of Shares
489
Previous 135 262.22%
Holding current value
$17,789
Previous $3,000 300.0%
% of portfolio
0.01%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

BUY
$21.96 - $27.6 $7,773 - $9,770
354 Added 262.22%
489 $12,000
Q2 2024

Jul 26, 2024

SELL
$20.34 - $23.73 $650 - $759
-32 Reduced 19.16%
135 $3,000
Q1 2024

May 08, 2024

BUY
$20.17 - $23.93 $3,368 - $3,996
167 New
167 $3,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Eagle Bay Advisors LLC Portfolio

Follow Eagle Bay Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Bay Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Bay Advisors LLC with notifications on news.